Objective:To explore whether the vaccination of COVID-19 vaccine affects the clinical pregnancy rate of assisted reproductive technology (ART).Methods:Based on a cross-sectional design, 17 611 cycles of ART treatment in 12 human-assisted reproductive institutions under Beijing Municipality from August 1, 2021, to July 31, 2022 were investigated, and their vaccination status and clinical pregnancy rate were investigated and analyzed.Results:The new crown vaccination rates of men and women receiving ART treatment were 58.83% (10 361/17 611) and 41.46% (7 301/17 611), respectively; 80.88% (5 864/7 250) of the couples did not complete the vaccination due to concerns about the safety or adverse reactions of the vaccine. The results of univariate analysis and logistic multivariate analysis showed whether vaccination with the new crown vaccine will not significantly affect the clinical pregnancy rate of artificial insemination or in vitro fertilization and embryo transfer (IVF-ET). The clinical pregnancy rate of fully vaccinated under artificial insemination was 10.74% (100/931), which was 11.10% (206/1 856) of both not vaccinated, there was no significant difference ( P=0.776), while adjusted OR=0.96, 95% CI: 0.74-1.24, P=0.766. The clinical pregnancy rate of fully vaccinated under IVF-ET was 41.88% (2 450/5 850), both not vaccinated was 40.92% (1 815/4 435), there was no significant difference ( P=0.330), while adjusted OR=1.02, 95% CI: 0.94-1.11, P=0.578. Conclusion:Vaccination against COVID-19 does not affect the clinical pregnancy rate of ART treatments. The low vaccination rate of the childbearing age group who needs to assist in pregnancy needs more attention.

Objective:To explore whether the vaccination of COVID-19 vaccine affects the clinical pregnancy rate of assisted reproductive technology (ART).Methods:Based on a cross-sectional design, 17 611 cycles of ART treatment in 12 human-assisted reproductive institutions under Beijing Municipality from August 1, 2021, to July 31, 2022 were investigated, and their vaccination status and clinical pregnancy rate were investigated and analyzed.Results:The new crown vaccination rates of men and women receiving ART treatment were 58.83% (10 361/17 611) and 41.46% (7 301/17 611), respectively; 80.88% (5 864/7 250) of the couples did not complete the vaccination due to concerns about the safety or adverse reactions of the vaccine. The results of univariate analysis and logistic multivariate analysis showed whether vaccination with the new crown vaccine will not significantly affect the clinical pregnancy rate of artificial insemination or in vitro fertilization and embryo transfer (IVF-ET). The clinical pregnancy rate of fully vaccinated under artificial insemination was 10.74% (100/931), which was 11.10% (206/1 856) of both not vaccinated, there was no significant difference ( P=0.776), while adjusted OR=0.96, 95% CI: 0.74-1.24, P=0.766. The clinical pregnancy rate of fully vaccinated under IVF-ET was 41.88% (2 450/5 850), both not vaccinated was 40.92% (1 815/4 435), there was no significant difference ( P=0.330), while adjusted OR=1.02, 95% CI: 0.94-1.11, P=0.578. Conclusion:Vaccination against COVID-19 does not affect the clinical pregnancy rate of ART treatments. The low vaccination rate of the childbearing age group who needs to assist in pregnancy needs more attention.

Osteoporotic vertebral compression fracture (OVCF) can lead to lower back pain and may be even accompanied by scoliosis, neurological dysfunction and other complications, which will affect the daily activities and life quality of patients. Vertebral augmentation is an effective treatment method for OVCF, but it cannot correct unbalance of bone metabolism or improve the osteoporotic status, causing complications like lower back pain, limited spinal activities and vertebral refracture. The post-operative systematic and standardized rehabilitation treatments can improve curative effect and therapeutic efficacy of anti-osteoporosis, reduce risk of vertebral refracture, increase patient compliance and improve quality of life. Since there still lack relevant clinical treatment guidelines for postoperative rehabilitation treatments following vertebral augmentation for OVCF, the current treatments are varied with uneven therapeutic effect. In order to standardize the postoperative rehabilitation treatment, the Spine Trauma Group of the Orthopedic Branch of Chinese Medical Doctor Association organized relevant experts to refer to relevant literature and develop the "Guideline for postoperative rehabilitation treatment following vertebral augmentation for osteoporotic vertebral compression fracture (2022 version)" based on the clinical guidelines published by the American Academy of Orthopedic Surgeons (AAOS) as well as on the principles of scientificity, practicality and advancement. The guideline provided evidence-based recommendations on 10 important issues related to postoperative rehabilitation treatments of OVCF.

Since December 2019, the corona virus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (2019-nCoV) has been reported in Wuhan, Hubei Province. Almost 70% of patients susceptible to 2019-nCoV are over age of 50 years, with extremely large proportion of critical illness and death of the elderly patients. Meanwhile, the elderly patients are at high risk of osteoporotic fractures especially osteoporotic vertebral compression fractures (OVCF). During the prevention and control of COVID-19 epidemic, orthopedists are confronted with the following difficulties including how to screen and protect OVCF patients, how to accurately diagnose and assess the condition of OVCF patients with suspected or confirmed COVID-19, and how to develop reasonable treatment plans and comprehensive protective measures in emergency and outpatient clinics. In order to standardize the diagnosis and treatment of patients with OVCF diagnosed with COVID-19, the authors jointly develop this expert consensus. The consensus systematically recommends the standardized emergency and outpatient screening and confirmation procedures for OVCF patients with suspected or confirmed COVID-19 and protective measures for emergency and outpatient clinics. Moreover, the consensus describes the grading and classification of OVCF patients diagnosed with COVID-19 according to the severity of illness and recommends different treatment plans and corresponding protective measures based on the different types and epidemic prevention and control requirements.

Hepatocellular carcinoma has a low early diagnostic rate, and there is a lack of highly sensitive and specific tumor markers. In recent years, fluid biopsy technique, represented by circulating free DNA (cfDNA), has become an auxiliary method for the diagnosis of cancer and has attracted more and more attention due to its advantages of noninvasiveness, convenience, and repeatability. With reference to the recent studies in China and foreign countries, this article summarizes and analyzes the advances in cfDNA in the diagnosis and treatment of hepatocellular carcinoma from the aspects of biological characteristics, detection techniques, and clinical application, so as to provide a basis for clinical diagnosis and treatment.